News - Townsend Investments
LATEST NEWS:
23rd March 2016 - NovaBiotics Presenting Three Abstracts at ECFS 2016

NOVABIOTICS ANNOUNCES THE ACCEPTANCE OF THREE ABSTRACTS FOR PRESENTATION AT ECFS 2016.

Three of NovaBiotics' recent studies from within the company's cystic fibrosis (CF) programmes have been selected for poster and oral e-poster presentations at Europe's premier CF conference, ECFS.  Data on the activity of Lynovex (NovaBiotics' novel antibacterial mucoactive CF therapy candidate) as a dry powder inhaled product, the activity of Lynovex against the CF bacterial pathogen Burkholderia spp and also data on the activity of Novamycin against Aspergillus spp and emerging CF fungal pathogens will be presented.



Go Back